medigraphic.com
Colegio de Medicina Interna de México.

2020, Número 5

<< Anterior Siguiente >>

Med Int Mex 2020; 36 (5)


Trombocitopenia inmunitaria primaria

Córdova-Pluma VH, Vega-López CA, Ortega-Chavarría MJ

Idioma: Español
Referencias bibliográficas: 37
Paginas: 660-669
Archivo PDF: 206.23 Kb.


RESUMEN

La trombocitopenia inmunitaria primaria, antes conocida como púrpura trombocitopénica inmunitaria, es la condición clínica caracterizada por la disminución de la población total de plaquetas mediada por la existencia de anticuerpos contra antígenos de membrana plaquetarios, lo que ocasiona la destrucción acelerada e incluso inhibe la producción de nuevas plaquetas. Las hemorragias mucocutáneas son predominantes, las petequias son las más características. Se clasifica de acuerdo con el tiempo de evolución, la severidad de los síntomas y la causa desencadenante. Es un diagnóstico de exclusión porque no se cuenta con una prueba diagnóstica específica. Esta revisión tiene como objetivo insistir en los conocimientos de la causa, fisiopatología, diagnóstico y tratamiento de la trombocitopenia inmunitaria primaria, diagnóstico que debe tenerse en mente durante la práctica clínica.


REFERENCIAS (EN ESTE ARTÍCULO)

  1. Abrahamson PE, Hall SA, Feudjo-Tepie M, Mitrani-Gold FS, Logie J. The incidence of idiopathic thrombocytopenic purpura among adults: a population-based study and literature review. Eur J Haematol 2009; 83: 83-89. DOI: 10.1111/j.1600-0609.2009.01247.x

  2. Sanz MA, Vicente García V, Fernández A, Sociedad Española de Hematología y Hemoterapia, Sociedad Española de Hematología y Oncología Pediátricas y col. Guidelines for diagnosis, treatment and monitoring of primary immune thrombocytopenia. Med Clin (Barc) 2012; 138: 261. doi: 10.1016/j.medcli.2011.11.011

  3. Pizzuto J, Ambriz R. Therapeutic experience on 934 adults with idiopathic thrombocytopenic purpura: Multicentric trial of the Cooperative Latin American group on Hemostasis and Thrombosis. Blood 1984; 64: 1179-1183.

  4. Kaushansky K. Historical review: megakaryopoiesis and thrombopoiesis. Blood 2008; 111 (3): 981. doi: 10.1182/ blood-2007-05-088500

  5. Amy E, Geddis M. Megakaryopoiesis. Semin Hematol 2010; 47 (3): 212-219. doi: 10.1053/j.seminhematol.2010.03.001

  6. Deutsch VR, Tomer A. Megakaryocyte development and platelet production. Br J Haematol 2006; 134 (5): 453. doi: 10.1111/j.1365-2141.2006.06215.x

  7. Wang C, Smith B, Ault K, Rinder H. Reticulated platelets predict platelet count recovery following chemotherapy. Transfusion 2002; 42 (3): 368. doi: 10.1046/j.1537- 2995.2002.00040.x

  8. Toltl LJ, Arnold DM. Pathophysiology and management of chronic immune thrombocytopenia: focusing on what matters. Br J Haematol 2011; 152 (1): 52-60. doi: 10.1111/j.1365-2141.2010.08412.x

  9. Lopez MA, Alvarado M, Medina L. Trombocitopenia inmune primaria diagnóstico y tratamiento. Española EA, 2015.

  10. Berchtold P. Wenger M. Autoantibodies against platelet glycoproteins in autoimmune thrombocytopenic purpura: Their clinical significance and response to treatment. Blood 1993; 81: 1246-1250.

  11. Jhonsen J. Pathogenesis in immune thrombocytopenia: new insights. Hematology 2012; 2012: 306-312. https:// doi.org/10.1182/asheducation.V2012.1.306.3798320

  12. Rodger G. Thrombocytopenia: Pathophysiology and classification. In: Wintrobe M. Wintrobe’s clinical hematology. Philadelphia: Lippincott Williams & Wilkins, 2009; 1289.

  13. Cines DB, Bussel JB, Liebman HA, Luning Prak ET. The ITP syndrome: Pathogenic and clinical diversity. Blood 2009; 113: 6511-6521. https://doi.org/10.1182/ blood-2009-01-129155

  14. Wilson Ruiz Gil. Diagnóstico y tratamiento de la púrpura trombocitopénica inmunológica. Rev Med Hered 2015; 26: 246-255.

  15. Awargal N, Spahr JE, Werner TL, Newton DL, Rodgers G. Acquired amegakaryocytic thrombocytopenic purpura. Am J Hematol 2006; 81: 132-135. doi: 10.1002/ajh.20510

  16. Thinelt Ch, Calverley D. Thrombocytopenia caused by immunologic platelet destruction. Wintrobe M. Wintrobe’s clinical hematology. Philadelphia: Lippincott Williams & Wilkins, 2009; 1292.

  17. Lo E, Deane S. Diagnosis and classification of immunemediated thrombocytopenia. Autoimmun Rev 2014; 13: 577-583. https://doi.org/10.1016/j.autrev.2014.01.026

  18. Neunert C, Arnold DM. Severe bleeding events in adults and children with primary immune thrombocytopenia: a systematic review: reply. J Thromb Haemost 2015; 13: 457-464. doi: 10.1111/jth.12813

  19. Provan D, Stasi R, Newland AC, et al. International consensus report on the investigation and management of primary immune thrombocytopenia. Blood 2010; 115: 168-186. doi: 10.1182/blood-2009-06-225565

  20. Fierro A. Púrpuras. Trombocitopenia inmune primaria. Pediatría integral 2012; XVI: 399-412.

  21. Davoren A, Bussel J, Curtis B, Moghaddam M, Aster R, McFarland J. Prospective evaluation of a new platelet glycoprotein (GP)-specific assay (PakAuto) in the diagnosis of autoimmune thrombocytopenia AITP). Am J Hematol 2005; 78 (3): 193. DOI: 10.1002/ajh.20309

  22. Alvarado-Ibarra M, Aguilar-Andrade C, Álvarez-Vera Jl, et al. Trombocitopenia inmunitaria primaria. Consenso 2016 por hematólogos del ISSSTE. Rev Hematol Mex 2016; 17 (4): 268-286.

  23. Rodeghiero F, Stasi R, Giagounidis A, et al. Long-term safety and tolerability of romiplostim in patients with primary immune thrombocytopenia: a pooled analysis of 13 clinical trials. Eur J Haematol 2013; 91: 423-436. doi: 10.1111/ejh.12181

  24. Sanz M. Long-term management of chronic immune thrombocytopenic purpura in adults. Int J Gen Med 2010; 3: 305-307. doi: 10.2147/IJGM.S4722

  25. Cheng Y, Wong R, Soo Y, et al. Initial treatment of immune thrombocytopenic púrpura with high-dose dexamethasone. N Engl J Med 2003; 349: 831-836. DOI: 10.1056/ NEJMoa030254

  26. López MA, Medina L, Alvarado M, Álvarez JL. Tratamiento de la púrpura trombocitopénica inmunitaria. Experiencia en un solo hospital. Med Int Méx 2015; 31: 3-12.

  27. Cheng G, Saleh MN, Marcher C, et al. Eltrombopag for management of chronic immune thrombocytopenia (RAISE): a 6-month, randomised, phase 3 study. Lancet 2011; 377: 393-402. doi: 10.1016/S0140-6736(10)60959-2

  28. Neunert C, Lim W, Crowther M, Cohen A, Solberg L, Crowther M. Review article: The American Society of Hematology 2011 evidence-based practice guideline for immune thrombocytopenia. Blood 2011; 117 (16): 4190- 4207. https://doi.org/10.1182/blood-2010-08-302984

  29. Kojouri K, Vesely S, Terrell D, George J. Splenectomy for adult patients with idiopathic thrombocytopenic purpura: A systematic literature review to assess long-term platelet count responses, prediction of response, and surgical complications. Blood 2004; 104: 2623-2634. doi: 10.1182/ blood-2004-03-1168

  30. Rodeghiero F, Ruggeri M. Short- and long-term risks of splenectomy for benign haematological disorders: Should we revisit the indications? Br J Haematol 2012; 158: 16-29. doi: 10.1111/j.1365-2141.2012.09146.x

  31. Marquínez-Alonso I, Escudero-Vilaplana V, Pernía S, Beléndez Bieler C, et al. The treatment for primary immune thrombocytopenia with romiplostim in adult and paediatric patients: use experience at a Spanish university hospital. J Clin Pharm Ther 2014; 39: 376-382. DOI: 10.1111/jcpt.12156

  32. Lozano ML, Revilla N, González-López TJ, et al. Real-life management of primary immune thrombocytopenia (ITP) in adult patients and adherence to practice guidelines. Ann Hematol 2016; 95: 1089-1098. doi: 10.1007/s00277- 016-2665-3

  33. Basciano PA, Bussel JB. Thrombopoietin-receptor agonists. Current Opinion in Hematology 2012; 19:392-398. DOI: 10.1097/MOH.0b013e328356e909

  34. Rice L. Treatment of immune thrombocytopenic purpura: focus on eltrombopag. Biologics 2009; 3: 151-157. doi: 10.2147/btt.2009.2984

  35. Vlachaki E, Papageorgiou V, Klonizakis F, et al. Total remission of severe immune thrombocytopenia after short term treatment with romiplostim. Hematol Rep 2011; 3: 1-2. doi: 10.4081/hr.2011.e20

  36. Patel VL, Mahévas M, Lee SY, et al. Outcomes 5 years after response to rituximab therapy in children and adults with immune thrombocytopenia. Blood 2012; 119: 5989-5995. doi: 10.1182/blood-2011-11-393975

  37. Zhang WG, Ji L, Cao XM, et al. Mycophenolate mofetil as a treatment for refractory idiopathic thrombocytopenic purpura. Acta Pharmacol Sin 2005; 26: 598-602. doi: 10.1111/j.1745-7254.2005.00088.x




2020     |     www.medigraphic.com